NorthWest Biotherapeutics Inc (NWBO)

[Investor082]

Most of the examples you provide are after FDA approval. It’s almost 20x revenue potential than UK.

UK spend about $6B annually in oncology drugs. US over $110B.

Markets will not value NWBO at $1B market cap on UK approval alone. Particularly when they took over 4.5 years to get there (without NICE reimbursement support in 2025). Markets will not trust NWBO to deliver on commercialization in any reasonable time frame given the rich history. Plus, they have no financial support from institutional investors and/or big pharma to lend credibility and accelerate that journey.

We would be lucky if we get a 100% spike at the UK approval. Ultimately, it gives up those gains in a couple of months as LP disappoints and endless dilution continues.